Gossamer Bio's Seralutinib shows promise for PAH and PH-ILD treatment. The main event comes with its topline results in Q4 ...

Q4 2024 Earnings Conference Call February 13, 2025 8:30 AM ETCompany ParticipantsJennifer Halchak - VP, IRKevin Ali - ...

Merck (MRK) is a leading global healthcare company recognized for its groundbreaking pharmaceutical products and vaccines.

Big pharma has come under a lot of scrutiny from regulators and consumers as sentiment sours on the industry. As such, the ...

Merck KGaA: Merck KGaA confirms discussions with Springworks Therapeutics, Inc. on potential acquisition 10-Feb-2025 / 20:06 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of ...

Organon (NYSE: OGN) today announced its results for the fourth quarter and full year ended December 31, 2024. “In 2024 we achieved our third year of constant currency revenue growth and delivered ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Merck booked just under $600 million last year in alliance revenues from the pair, but its attention is now moving to new therapies including sotatercept, a TGF-beta-targeting PAH drug Merck ...

Merck & Co has said building its cardiovascular medicines business is central to its strategy to manage the loss of patent protection of cancer juggernaut Keytruda in five years, and new studies ...

To an extent, it depends on how you look at the numbers. Boeing reported $5.46 per share in GAAP net losses in Q4, and losses of $18.36 for the year. The company also continued to burn cash ...